Zegerid Approval History

Zegerid (omeprazole and sodium bicarbonate) is proton-pump inhibitor and antacid combination for the treatment of duodenal ulcer, heartburn and other symptoms associated with gastroesophageal reflux disease (GERD), and erosive esophagitis.

FDA Approval History for Zegerid

DateArticle
Feb 24, 2006Santarus Announces FDA Action Date of February 27, 2006 for Zegerid Capsules NDA
Jul 26, 2005Santarus Announces FDA Acceptance of New Drug Application For Zegerid Chewable Tablets
Jun 28, 2005Santarus Announces FDA Acceptance of New Drug Application For Zegerid Capsules; FDA Action Expected in Early 2006 on NDA for First Immediate-Release Proton Pump Inhibitor in Capsule Formulation
May 27, 2005Santarus Submits New Drug Application for Zegerid Chewable Tablets
Apr 28, 2005Santarus Submits New Drug Application for Zegerid Capsules; NDA for First Immediate-Release PPI Capsule Submitted Ahead of Previously Announced Third Quarter Target
Jun 15, 2004Approval Zegerid Santarus, Inc. - Treatment for Heartburn/GERD, Erosive Esophagitis, Duodenal Ulcers
Apr 29, 2004FDA Accepts for Filing Santarus' New Drug Application for Rapinex Powder for Oral Suspension 40mg

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)